We recently had the pleasure of welcoming representatives from the Norwegian Parliament’s Standing Committee on Business and Industry, together with partners from industry and the life science ecosystem, to the Oslo Cancer Cluster Incubator.
The visit focused on an important question: what do policymakers need from companies and innovation environments to better support the Norwegian health industry — across both emerging startups and established players? A key takeaway from the discussion was the value of direct engagement with companies and researchers, and the importance of seeing innovation work first-hand.
During the visit, the delegation toured the Oslo Cancer Cluster Innovation Park and met with both small and large actors in Norwegian life sciences, including Oncosyne and Thermo Fisher Scientific. This provided an opportunity to highlight how collaboration across company sizes, disciplines, and sectors is essential for building a strong and competitive health innovation ecosystem.
At Oncosyne, we were pleased to open our laboratories and share insights into how we work with patient-derived tumor models to support translational cancer research, functional in vitro diagnostics and drug development. Constructive dialogue between policymakers, industry, and research-driven companies is critical to enabling innovation that can ultimately improve patient outcomes.
We thank all participants for an engaging and insightful visit and look forward to continued dialogue on how to strengthen Norway’s position in life science innovation.